المؤلفون: G. G. Krivoborodov, E. I. Tur, D. A. Shirin, Г. Г. Кривобородов, Е. И. Тур, Д. А. Ширин

المصدر: Meditsinskiy sovet = Medical Council; № 4 (2021); 121-126 ; Медицинский Совет; № 4 (2021); 121-126 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: мирабегрон, neurogenic detrusor overactivity, idiopathic detrusor overactivity, detrusor, M-anticholinergics, β3-adrenergic receptor agonists, mirabegron, нейрогенная детрузорная гиперактивность, идиопатическая детрузорная гиперактивность, детрузор, М-холиноблокаторы, агонисты β3-адренорецепторов

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6099/5558; Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U. et al. The Standardisation of Terminology of Lower Urinary Tract Function: Report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–178. doi:10.1002/nau.10052.; Eapen R.S., Radomski S.B. Review of the Epidemiology of Overactive Bladder. Res Rep Urol. 2016;8:71–76. doi:10.2147/RRU.S102441.; Liu H.T., Chancellor M.B., Kuo H.C. Urinary Nerve Growth Factor Levels Are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection. Eur Urol. 2009;56(4):700–706. doi:10.1016/j.eururo.2008.04.037.; Lowe E.M., Anand P., Terenghi G., Williams-Chestnut R.E., Sinicropi D.V., Osborne J.L. Increased Nerve Growth Factor Levels in the Urinary Bladder of Women with Idiopathic Sensory Urgency and Interstitial Cystitis. Br J Urol. 1997;79(4):572–577. doi:10.1046/j.1464-410x.1997.00097.x.; Okragly A.J., Niles A.L., Saban R., Schmidt D., Hoffman R.L., Warner T.F. et al. Elevated Tryptase, Nerve Growth factor, Neurotrophin-3 and Glial Cell Line-Derived Neurotrophic Factor Levels in the Urine of Interstitial Cystitis and Bladder Cancer Patients. J Urol. 1999;161(2):438–441. doi:10.1016/S0022-5347(01)61915-3.; Michel M.C., Chapple C.R. Basic Mechanisms of Urgency: Preclinical and Clinical Evidence. Eur Urol. 2009;56(2):298–307. doi:10.1016/j.eururo.2009.05.028.; Cucchi A., Quaglini S., Rovereto B. Relationships between Micturition Urgency and Involuntary Voiding Dynamics in Men with Urinary Incontinence from Idiopathic Detrusor Overactivity. J Urol. 2007; 178(2):563–567. doi:10.1016/j.juro.2007.03.122.; Cucchi A., Quaglini S., Siracusano S., Rovereto B. Urgency Degree and Bladder Contraction Velocity: Sequential Changes in Women with Idiopathic Detrusor Overactivity. Neurourol Urodyn. 2006;25(2):123–127. doi:10.1002/nau.20217.; Мазо Е.Б., Кривобородов Г.Г. Гиперактивный мочевой пузырь. М.: Вече; 2003. 160 p.; Moore E.E., Jackson S.L., Boyko E.J., Scholes D., Fihn S.D. Urinary Incontinence and Urinary Tract Infection: Temporal Relationships in Postmenopausal Women. Obstet Gynecol. 2008;111(2 Pt 1):317–323. doi:10.1097/AOG.0b013e318160d64a.; Homma Y., Kakizaki H., Yamaguchi O., Yamanishi T., Nishizawa O., Yokoyama O. et al. Assessment of Overactive Bladder Symptoms: Comparison of 3-Day Bladder Diary and the Overactive Bladder Symptoms Score. Urology. 2011;77(1):60–64. doi:10.1016/j.urology.2010.06.044.; Van Brummen H.J., Heintz A.P., van der Vaart C.H. The Association between Overactive Bladder Symptoms and Objective Parameters from Bladder Diary and Filling Cystometry. Neurourol Urodyn. 2004;23(1):38–42. doi:10.1002/nau.10162.; Buchsbaum G.M., Albushies D.T., Guzick D.S. Utility of Urine Reagent Strip in Screening Women with Incontinence for Urinary Tract Infection. Int Urogynecol J Pelvic Floor Dysfunct. 2004;15(6):391–393. doi:10.1007/s00192-004-1192-2.; Arinzon Z., Shabat S., Peisakh A., Berner Y. Clinical Presentation of Urinary Tract Infection (UTI) Differs with Aging in Women. Arch Gerontol Geriatr. 2012;55(1):145–147. doi:10.1016/j.archger.2011.07.012.; Nitti V.W., Rovner E.S., Bavendam T. Response to Fesoterodine in Patients with an Overactive Bladder and Urgency Urinary Incontinence Is Independent of the Urodynamic findIng of Detrusor Overactivity. BJU Int. 2010;105(9):1268–1275. doi:10.1111/j.1464-410X.2009.09037.x.; Rovner E., Kennelly M., Schulte-Baukloh H., Zhou J., Haag-Molkenteller C., Dasgupta P. Urodynamic Results and Clinical Outcomes with Intradetrusor Injections of OnabotulinumtoxinA in a Randomized, Placebo-Controlled Dose-Finding Study in Idiopathic Overactive Bladder. Neurourol Urodyn. 2011;30(4):556–562. doi:10.1002/nau.21021.; Jeffcoate T.N., Francis W.J. Urgency Incontinence in the Female. Am J Obstet Gynecol. 1966;94(5):604–618. doi:10.1016/0002-9378(66)90395-4.; Fantl J.A., Wyman J.F., McClish D.K., Harkins S.W., Elswick R.K., Taylor J.R., Hadley EC. Efficacy of Bladder Training in Older Women with Urinary Incontinence. JAMA. 1991;265(5):609–613. doi:10.1001/jama.1991.03460050063021.; O’Donnel P.D. Biofeedback Therapy. In: Raz S. (ed.). Female Urology. 2nd ed., Philadelphia: W.B. Saunders; 1996, рр. 253–261.; Hay-Smith E.J., Bø K., Berghmans L.C., Hendriks H.J., de Bie R.A., van Waalwijk van Doorn E.S. WITHDRAWN: Pelvic Floor Muscle Training for Urinary Incontinence in Women. Cochrane Database Syst Rev. 2007;(1):CD001407. doi:10.1002/14651858.CD001407.pub2.; Burkhard F.C., Bosch J.L.H.R., Cruz F., Lemack G.E., Nambiar A.K., Thiruchelvam N., Tubaro A. EAU Guidelines on Urinary Incontinence. Arnhem: EAU Guidelines Office; 2020. Available at: https://uroweb.org/guideline/urinary-incontinence/.; Shamliyan T., Wyman J., Kane R.L. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012. Report No.: 11(12)-EHC074-EF. Available at: https://www.ncbi.nlm.nih.gov/books/NBK92960/.; Sacco E., Bientinesi R. Mirabegron: A Review of Recent Data and Its Prospects in the Management of Overactive Bladder. Ther Adv Urol. 2012;4(6):315–324. doi:10.1177/1756287212457114.; Dawood O., El-Zawahry A. Mirabegron. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available at: https://www.ncbi.nlm.nih.gov/books/NBK538513/.; Abrams P., Andersson K.E., Buccafusco J.J., Chapple C., de Groat W.C., Fryer A.D. et al. Muscarinic Receptors: Their Distribution and Function in Body Systems, and the Implications for Treating Overactive Bladder. Br J Pharmacol. 2006;148(5):565–578. doi:10.1038/sj.bjp.0706780.; Andersson K.E. On the Site and Mechanism of Action of β3-Adrenoceptor Agonists in the Bladder. Int Neurourol J. 2017;21(1):6–11. doi:10.5213/inj.1734850.425.; Igawa Y., Michel M.C. Pharmacological Profile of β3-Adrenoceptor Agonists in Clinical Development for the Treatment of Overactive Bladder Syndrome. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(3):177–183. doi:10.1007/s00210-012-0824-1.; Igawa Y., Aizawa N., Homma Y. Beta3-Adrenoceptor Agonists: Possible Role in the Treatment of Overactive Bladder. Korean J Urol. 2010;51(12):811– 818. doi:10.4111/kju.2010.51.12.811.; Andersson K.E., Martin N., Nitti V. Selective β₃-Adrenoceptor Agonists for the Treatment of Overactive Bladder. J Urol. 2013;190(4):1173–1180. doi:10.1016/j.juro.2013.02.104.; Andersson K.E., Arner A. Urinary Bladder Contraction and Relaxation: Physiology and Pathophysiology. Physiol Rev. 2004;84(3):935–986. doi:10.1152/physrev.00038.2003.; Yamaguchi O., Marui E., Kakizaki H., Homma Y., Igawa Y., Takeda M. et al. Phase III, Randomised, Double-Blind, Placebo-Controlled Study of the β3-Adrenoceptor Agonist Mirabegron, 50 mg Once Daily, in Japanese Patients with Overactive Bladder. BJU Int. 2014;113(6):951–960. doi:10.1111/bju.12649.; Ichihara K., Masumori N., Fukuta F., Tsukamoto T., Iwasawa A., Tanaka Y. A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and Its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction. J Urol. 2015;193(3): 921–926. doi:10.1016/j.juro.2014.09.091.; Gratzke C., van Maanen R., Chapple C., Abrams P., Herschorn S., Robinson D. et al. Long-Term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018;74(4):501–509. doi:10.1016/j.eururo.2018.05.005.; https://www.med-sovet.pro/jour/article/view/6099

الاتاحة: https://www.med-sovet.pro/jour/article/view/6099
https://doi.org/10.21518/2079-701X-2021-4-121-126

المؤلفون: Bacinschi, N.G., Bachinsky, N., Бачинский, Н., Vasilache, E., Caracaş, A.

المصدر: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 63 (3) 266-271

مصطلحات موضوعية: bronhodilatatoare, bronhopneumopatia obstructivă cronică, beta-2-adrenomimetice, M-colinoblocante, metilxantine, bronchodilators, chronic obstructive pulmonary disease, beta 2 -adrenomimetics, anticholinergics, methylxanthines, бронходилататоры, хроническая обструктивная болезнь легких, бета-2-адреномиметики, М-холиноблокаторы, метилксантины

وصف الملف: application/pdf

Relation: https://ibn.idsi.md/vizualizare_articol/91314; urn:issn:18570011

الاتاحة: https://ibn.idsi.md/vizualizare_articol/91314

المؤلفون: Спиридоненко, В. В.

المصدر: Health of Man; No. 3 (2019); 27-32 ; Здоровье мужчины; № 3 (2019); 27-32 ; Здоров'я чоловіка; № 3 (2019); 27-32 ; 2412-5547 ; 2307-5090

مصطلحات موضوعية: нейрогенный гиперрефлекторный мочевой пузырь, солифенацин, селективные м-холиноблокаторы, 616.62-008.222-02, 616.8-08, нейрогенний гіперрефлекторний сечовий міхур, соліфенацин, селективні м-холіноблокатори, neurogenic hyperreflex bladder, solifenacin, selective m-anticholinergics

وصف الملف: application/pdf

Relation: http://health-man.com.ua/article/view/185347/184944; http://health-man.com.ua/article/view/185347

الاتاحة: http://health-man.com.ua/article/view/185347
https://doi.org/10.30841/2307-5090.3.2019.185347

المؤلفون: Bacinschi, Nicolae, Vasilache, Eugenia, Caracaş, Anastasia

المصدر: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 63 No. 3 (2019): Medical Sciences; 266-271 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 63 Nr. 3 (2019): Ştiinţe medicale; 266-271 ; Вестник Академии Наук Молдовы. Медицина; Том 63 № 3 (2019): Медицина; 266-271 ; 1857-0011

مصطلحات موضوعية: бронходилататоры, хроническая обструктивная болезнь легких, бета-2-адреномиметики, М-холиноблокаторы, метилксантины, inhaled glucocorticoids, obstructive pulmonary disease, M-cholinoblocks, anticholinergics, methylxanthines, bronhodilatatoare, bronhopneumopatia obstructivă cronică, beta-2-adrenomimetice, M-colinoblocante, metilxantine

وصف الملف: application/pdf

Relation: https://bulmed.md/bulmed/article/view/3128/3128; https://bulmed.md/bulmed/article/view/3128

الاتاحة: https://bulmed.md/bulmed/article/view/3128

المؤلفون: E. S. Korshunova, M. N. Korshunov, S. P. Darenkov, Е. С. Коршунова, М. Н. Коршунов, С. П. Даренков

المصدر: Urology Herald; Том 5, № 4 (2017); 84-95 ; Вестник урологии; Том 5, № 4 (2017); 84-95 ; 2308-6424 ; 10.21886/2308-6424-2017-5-4

مصطلحات موضوعية: противопаркинсонические средства, Parkinson’s disease, muscarinic receptor antagonist, antiparkinsonian agents, болезнь Паркинсона, М-холиноблокаторы

وصف الملف: application/pdf

Relation: https://www.urovest.ru/jour/article/view/183/148; Иллариошкин С.Н., Яхно Н.Н. Болезнь Паркинсона и расстройства движений. М.: ООО Диалог; 2008.; Левин О.С., Федорова Н.В. Болезнь Паркинсона.- 5-е изд.-М.: Медпресс информ; 2015.; Голубев В.Л., Левин Я.И., Вейн А.М. Болезнь Паркинсона и синдром Паркинсонизма. Москва: МЕДпресс; 1999.; Экстрапирамидные расстройства. Руководство по диагностике и лечению. Под ред. Штока В.Н., Ивановой-Смоленской И.А., Левина О.С. М.:МЕД-пресс- информ; 2002.; Stocchi F, Torti M, Palleschi G. Bladder dysfunction in Parkinsons Disease and other parkinsonism. In book: Olanow CW, Stocchi F, Lang A. Parkinson’s Disease: Non-Motor and Non-Dopaminergic Features. Wiley-Blackwell; 2011.; Nomura S, Ishido Т, Teranishi J, Makiyama K. Long-term analisis of suprapubic cystostomy drainage in patients with neurogenic bladder. Urol Int. 2000;65(4):185-9.; O’Donnell PD. Parkinson’s disease. Incontinence in Adults. 1997.; Коршунова Е.С. Диагностика и лечение симптомов нижних мочевых путей у больных болезнью Паркинсона в сочетании и без доброкачественной гиперплазии простаты: Автореферат дис. канд. мед. наук. М., 2006.; Кузьмина С.В., Доброскок А.М., Кузьмин И.В. Расстройства мочеиспускания при болезни Паркинсона. Урологические ведомости. 2016;6(4):28-32. doi:10.17816/uroved6428-32; Кривобородов Г.Г., Гехт А.Б., Коршунова Е.С. Тибиальная нейромодуляция в лечении нейрогенной детрузорной гиперактивности при болезни Паркинсона. Урология. 2006;(4):3-6.; Мазуренко Д.А. Дифференциальная диагностика и лечение расстройств мочеиспускания у больных болезнью Паркинсона: Автореферат дис. канд. мед. наук. М., 2005.; https://www.urovest.ru/jour/article/view/183

الاتاحة: https://www.urovest.ru/jour/article/view/183
https://doi.org/10.21886/2308-6424-2017-5-4-84-95

المؤلفون: Дейко, Роман Данилович, Штриголь, Сергій Юрійович, Лар’яновська, Юлія Борисівна, Горбач, Тетяна Вікторівна, Губіна-Вакулик, Галина Іванівна, Дев'яткіна, Наталія Миколаївна, Штриголь, Діана В’ячеславівна, Штрыголь, Сергей Юрьевич, Ларьяновская, Юлия Борисовна, Горбач, Татьяна Викторовна, Губина-Вакулик, Галина Ивановна, Девяткина, Наталья Николаевна, Штрыголь, Диана Вячеславовна, Deiko, R. D., Shtrygol’, S. Yu., Laryanovskaya, Yu. B., Gorbach, T. V., Gubina-Vakulik, G. I., Devyatkina, N. M., Shtrygol’, D. V.

مصطلحات موضوعية: хвороба Альцгеймера, патогенез, М-холіноблокатори, експеримент, болезнь Альцгеймера, М-холиноблокаторы, эксперимент, Alzheimer’s disease, pathogenesis, M-cholinoblockers, experiment

Relation: Хронічна блокада центральних мускаринових рецепторів у щурів відтворює первинні патогенетичні ланки хвороби Альцгеймера / Р.Д. Дейко , С.Ю. Штриголь, Ю.Б. Лар’яновська [та ін.] // Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії. – 2017. – Т. 17, вип. 3 (59). – С. 13–25.; УДК 616.831-005.1:616.8-009:616-08:577.112.6; http://repository.pdmu.edu.ua/handle/123456789/10332

الاتاحة: http://repository.pdmu.edu.ua/handle/123456789/10332

المؤلفون: I. A. Apolikhina, A. S. Chochueva, A. S. Saidova, E. A. Gorbunova, И. А. Аполихина, А. С. Чочуева, А. С. Саидова, Е. А. Горбунова

المصدر: Meditsinskiy sovet = Medical Council; № 2 (2017); 122-127 ; Медицинский Совет; № 2 (2017); 122-127 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-2

مصطلحات موضوعية: ургентность, adrenergic receptors, muscarinic receptors, M-cholinoblockers, beta-3 agonists, mirabegron, urgency, адренорецепторы, мускариновые рецепторы, М-холиноблокаторы, бета- 3-адреномиметик, мирабегрон

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1735/1681; Abrams P. The standartisation of terminology of lower urinary tract function. Neurourol. and Urodyn, 2002, 21: 167-178.; Гаджиева Ж.К. Нарушения мочеиспускания: руководство. Под ред. Ю.Г. Аляева. М.: ГЭОТАР-Медиа, 2010. 176 с.; Пушкарь Д.Ю. Гиперактивный мочевой пузырь у женщин. М.: МЕД пресс-информ, 2003. 160 с.; Джавад-Заде М.Д., Державин В.М., Вишневский Е.Л. Нейрогенные дисфункции мочевого пузыря. М.: Медицина, 1989.; Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A populationbased prevalence study. BJU Int, 2001, 87: 760–6.; Вишневский Е.Л., Пушкарь Д.Ю., Лоран О.Б., Данилов В.В., Вишневский А.Е. Урофлоуметрия. М., 2004: 263, 176–183, 183–208.; Moller LA, Lose G, Jorgensen T. Risk factors lower urinary tract symptoms in women 40 to 60 years of age. Obstet. Gynecol., 2000, 96: 446–51.; Cruz F. Vanilloid receptor and detrusor instability. Neurology and Urodynamics, 2009: 29–34.; Takeda M, Obara K, Mizusawa T et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther., 1999, 288, 3: 1367–1373.; Takeda H, Yamazaki Y, Akahane M et al. Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J. Pharmacol. Exp. Ther., 2000, 293(3): 939–945.; Otsuka A, Shinbo H, Matsumoto R et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 377(4–6): 473–481.; Liu Hsin-Tzu, Chancellor MB, Kuo H-Ch. Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection. European urology, 2009, 56: 700-707.; Liu Hsin-Tzu, Chancellor MB, Kuo H-Ch. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU international, 2009, 103(12): 1668-72.; Lesch KP, Merschdorf U. Impulsivity, aggression, and serotonin: a molecular psychobiological perspective. Behav Sci Law, 2000, 18: 581-604.; Zifa E, Fillion G. 5-Hydroxytryptamine receptors. Pharmacol. Rev., 1992, 44: 401-458.; Michel M, Ochodnicky P, Homma Y and Igawa Y. β-adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther, 2011, 131: 40–49.; Stenberg F, Heimer G, Ulmsten U. The prevalence of urogenital symptoms in postmenopausal women. Maturitas, 1995, 22(Suppl): 17–20.; Кулаков В.И., Аполихина И.А. Недержание мочи у женщин: новые возможности в диагностике и лечении. Гинекология, 2004, 4(3): 103–5.; Groat WC. Afferent nerve regulation of bladder function in health and disease. Handb. Exp. Pharmacol., 2009, 194: 91-138.; Abrams P and Wein. Overactive bladder and its treatments. Urology, 2000, 55(sup.).; Mukerji G et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. I. Urol., 2006, 176(1): 367-373.; Mulsant B, Pollock B, Kirshner M, Shen C, Dodge H and Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry, 2003, 60: 198–203.; Milsom I, Abrams P, Cardozo L, Roberts R, Thuroff J, Wein A. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int., 2001, 87: 760–766.; Wein AJ Rackley R.R. Overactive bladder: a better understanding of pathophysiology, diagnosis and management J Urol, 2006, 175(3 Pt 2): S5–10; Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther., 1999, 288: 1367–1373.; Sacco E, Tienforti D, D’Addessi A, Pinto F, Racioppi M, Totaro A, D’Agostino D, Marangi F, Bassi P. Social, economic, and health utility considerations in the treatment of overactive bladder. J. Urol., 2010, 2: 11–24.; Gruneberger A. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. Br. J. Obstetr. Gynaecol., 1984, 91: 275–278.; FDA Summary of safety and efficacy as basis for Advisory Committee briefing document for mirabegron, 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Reproductive HealthDrugsAdvisoryCommittee/UCM298284.pdf; Chapple C, Amarenco G, Lopez Aramburu M, Everaert K, Liehne J, Lucas M et al. A proof-ofconcept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn, 2013a, 32: 1116–1122.; Chapple C, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele J, Bosman B et al. (2013b) A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J, 24: 1447–1458.; Nitti V, Herschorn S, Auerbach S et al. The selective [beta] 3-adrenoreceptor agonist mirabegron is effective and well tolerated in patients with overactive bladder syndrome. J. Urol., 2011, 185(4): e783–e784.; Khullar V, Amarenco G, Angulo JC et al. Efficacy and tolerability of mirabegron, a β(3)- adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur. Urol., 2013, 63(2): 283–295.; Chapple C, Kaplan S, Mitcheson H et al. Randomised, double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)adrenoceptor agonist, in overactive bladder (OAB). Eur. Urol., 2013, 62(2): 296–305.; Rossanese M, Novara G, Challacombe B, Iannetti A, Dasgupta P and Ficarra V. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a beta(3)-adrenoceptor agonist (mirabegron) for overactive bladder (OAB). BJU Int, 2015, 115: 32–40.; Rosa G, Ferrero S, Nitti V, Wagg A, Saleem T and Chapple C. Cardiovascular safety of beta3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol, 2016, 69: 311–323.; Baber RJ, Panay N, Fenton A и рабочая группа IMS, 2016.; https://www.med-sovet.pro/jour/article/view/1735

الاتاحة: https://www.med-sovet.pro/jour/article/view/1735
https://doi.org/10.21518/2079-701X-2017-2-122-127

المؤلفون: I A Apolikhina, I S Ibinaeva, A I Zheleznyakova

المصدر: Гинекология, Vol 10, Iss 1, Pp 52-55 (2008)

مصطلحات موضوعية: недержание мочи, м-холиноблокаторы, мочевой пузырь, антихолинергические препараты, Gynecology and obstetrics, RG1-991

وصف الملف: electronic resource

Relation: https://gynecology.orscience.ru/2079-5831/article/view/27922; https://doaj.org/toc/2079-5696; https://doaj.org/toc/2079-5831

URL الوصول: https://doaj.org/article/07dc236daed14394bac68a025a963d0b

المؤلفون: G. Kasyan R., I. Konovalov V., Г. Касян Р., И. Коновалов В.

المصدر: Research and Practical Medicine Journal; Том 3, № 2 (2016); 37-44 ; Исследования и практика в медицине; Том 3, № 2 (2016); 37-44 ; 2410-1893 ; 2409-2231 ; 10.17709/2409-2231-2016-2

مصطلحات موضوعية: alpha-blockers, benign prostatic hyperplasia, combination therapy of LUTS, M-anticholinergics, lower urinary tract symptoms, альфа-блокаторы, доброкачественная гиперплазия предстательной железы, комбинированная терапия СНМП, М-холиноблокаторы, симптомы нижних мочевых путей

وصف الملف: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/136/137; Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61 (1): 37–49.; Chung D. E., Sandhu J. S. Overactive bladder and outlet obstruction in men. Curr Urol Rep. 2011; 12 (1): 77–85. doi:10.1007/s11934–010–0157 x.; Speakman M.J. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): more than treating symptoms? Eur Urol Suppl. 2008; 7: 680–689.; Irwin D. E., Milsom I., Hunskaar S., Reilly K., Kopp Z., Herschorn S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50 (6): 1306–1314.; Sexton C. C., Coyne K. S., Kopp Z. S., Irwin D. E., Milsom I., Aiyer L. P., et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 (Suppl 3): 12–23. doi:10.1111/j.1464–410X.2009.08369.x.; Irwin D. E., Kopp Z. S., Agatep B., Milsom I., Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011; 108: 1132–1138. doi:10.1111/j.1464–410X.2010.09993.x. Epub 2011 Jan 13.; Kupelian V., Wei J. T., O’Leary M. P., Kusek J.W., Litman H.J., Link C. L., et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006; 166 (21): 2381–2387.; Coyne K. S., Wein A.J., Tubaro A., Sexton C. C., Thompson C. L., Kopp Z. S., et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 2009; 103 (Suppl 3): 4–11. doi:10.1111/j.1464–410X.2009.08371.x.; Emberton M., Marberger M., de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract. 2008; 62 (1): 18–26.; Sells H., Donovan J., Ewings P., MacDonagh R. P. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int 2000; 85 (4): 440–445.; Peters T.J., Donovan J. L., Kay H. E., Abrams P., de la Rosette J.J., Porru D., et al. The International Continence Society “Benign Prostatic Hyperplasia” study: the bothersomeness of urinary symptoms. J Urol. 1997; 157 (3): 885–889.; Häkkinen J. T., Hakama M., Huhtala H., Shiri R., Auvinen A., Tammela T. L., et al. Impact of LUTS using bother index in DANPSS 1 questionnaire. Eur Urol. 2007; 51 (2): 473–477.; Asplund R. Nocturia: consequences for sleep and daytime activities and associated risks. Eur Urol. 2005; 3 (Suppl): 24–32.; Gravas S., Bach T., Bachmann A., Drake M., Gacci M., Gratzke C., et al. EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) 2016. Available at: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Management-of-non-neurogenicmale-LUTS 2016.pdf (дата обращения: 01.02.2016).; McVary K. T., Roehrborn C.G., Avins A. L., Barry MJ., Bruskewitz R. C., Donnell R.F, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185 (5): 1793–1803. doi:10.1016/j.juro.2011.01.074. Epub 2011 Mar 21.; Roehrborn C.G. Clinical management of lower urinary tract symptoms with combined medical therapy. BJU Int. 2008; 102 Suppl 2: 13–17. doi:10.1111/j.1464–410X.2008.08088.x.; van Kerrebroeck P., Jardin A., Laval K.U., van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2000; 37: 306–313.; Chapple C. R., Al-Shukri S.H., Gattegno B., et al. Tamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. Eur Urol. 2005; 4 Suppl: 33–44.; Narayan P., Evans C. P., Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003; 170: 498–502.; Chapple C. R., Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006; 49: 651–658.; Lee J. Y., Kim H.W., Lee S.J., Koh J. S., Suh H.J., Chancellor M. B., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004; 94 (6): 817–820.; McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006; 12: S122–128.; Кривобородов Г. Г. Симптомы нижних мочевыводящих путей. Урология. 2014; 1: 49–54.; Гаджиева З. К., Казилов Ю. Б., Аляев Ю. Г., Абоян И. А., Казилов Б. Р. Нарушения мочеиспускания. Все ли мы о них знаем? Урология. 2014; 1: 20–26.; Пушкарь Д.Ю., Раснер П.И. Опыт применения холинолитиков в лечении больных с аденомой предстательной железы с симптомами нижних мочевыводящих путей. Урология. 2011; 2: 80–85.; Велиев Е.И., Голубцова Е.Н., Дадашев Э.О. Необходимость и безопасность комбинированной лекарственной терапии пациентов с нарушениями мочеиспускания. Урология. 2012; 4: 92–96.; MacDiarmid S. A., Peters K. M., Chen A., Armstrong R. B., Orman C., Aquilina J. W., et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebocontrolled study. Mayo Clin Proc 2008; 83 (9): 1002–1058. doi:10.4065/83.9.1002.; Chapple C., Herschorn S., Abrams P., Sun F., Brodsky M., Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009; 56 (3): 534–541. doi:10.1016/j. eururo.2008.11.026. Epub 2008 Nov 24.; Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to -blocker treated men with residual urgency and frequency. J Urol. 2009; 182 (6): 2825–2830. doi:10.1016/j.juro.2009.08.023. Epub 2009 Oct 17.; Yamaguchi O., Kakizaki H., Homma Y., Takeda M., Nishizawa O., Gotoh M., et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms-ASSIST, randomized controlled study. Urology. 2011; 78 (1): 126–133. doi:10.1016/j.urology.2011.02.055. Epub 2011 May 23.; Berry S.J., Coffey D. S., Walsh P. C., Ewing L. L. The development of human benign prostratic hyperplasia with age. J Urology. 1984; 132 (3): 474–479.; Van Kerrebroeck P., Chapple C., Drogendijk T., Klaver M., Sokol R., Speakman M., et al; NEPTUNE Study Group. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013; 64 (16): 1003–1012. doi:10.1016/j.eururo.2013.07.034. Epub 2013 Aug 3.; Drake M.J., Chapple C., Sokol R., Oelke M., Traudtner K., Klaver M., et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015; 67 (2): 262–270. doi:10.1016/j.eururo.2014.07.013. Epub 2014 Jul 25.; Nazir J., Heemstra L., van Engen A., Hakimi Z., Ivanescu C. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia. BMC Urol. 2015 May 9;15:41. doi:10.1186/s12894–015–0031–8.; https://www.rpmj.ru/rpmj/article/view/136

الاتاحة: https://www.rpmj.ru/rpmj/article/view/136
https://doi.org/10.17709/2409-2231-2016-3-2-5

المؤلفون: A. S. Belevskiy, А. С. Белевский

المصدر: PULMONOLOGIYA; Том 26, № 1 (2016); 73-78 ; Пульмонология; Том 26, № 1 (2016); 73-78 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2016-26-1

مصطلحات موضوعية: индакатерол, analysis, chronic obstructive pulmonary disease, beta-2-agonists, anticholinergics, glycopyrronium bromide, indacaterol, анализ, хроническая обструктивная болезнь легких, b2-агонисты, М-холиноблокаторы, гликопиррония бромид

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/675/597; http://www.who.int/respiratory/copd; http://ria.ru/society/20141210/1037570497; Воробьев П.А., Авксентьева М.В., Борисенко О.В. и др. Клинико-экономический анализ. М.: Ньюдиамед; 2008.; Крысанов И.С. Анализ стоимости хронической обструктивной болезни легких в Российской Федерации. Качественная клиническая практика. 2014; 2: 51–56.; Wacker M.E., Jörres R.A., Schulz H. et al. COSYCONET-Consortium. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respir. Med. 2016; 111: 39–46.; Ehteshami-Afshar S., FitzGerald J.M., Doyle-Waters M.M., Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Intern. J. Tub. Lung Dis. 2016; 20 (1): 11–23.; Dahl R., Chung K.F., Buhl R. et al. On behalf of the INVOLVE Study Investigators. Efficacy of a new once-daily, long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65; 473–479.; Kornmann O., Dahl R., Centanni S. et al. INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-mg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur. Respir. J. 2011; 37 (2): 273–279.; Зырянов С.К., Жуденков К.В. Экономическое бремя ХОБЛ и пути оптимизации расходов: фокус на новые длительно действующие бронходилататоры. Практическая фармакоэкономика. Бронхопульмонология. М.: Издательский дом «Ремедиум». 2012.; Зырянов С.К., Жуденков К.В. Фармакоэкономическая оценка применения М-холинолитиков при лечении хронической обструктивной болезни легких в качестве базисной терапии и при обострениях. Практическая фармакоэкономика. 2014; 2: 43–52.; Hizava N. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Intern. J. COPD. 2015: 10: 1093–1102.; Mollen V.D., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim. Care Respir. J. 2012; 21 (1): 101–108.; Rossi A., Zanardi E., Poletti V., Cazzola M. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. Intern. J. COPD. 2015: 10: 1383–1392.; Bateman E.D., Ferguson G.T. Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42: 1484–1494.; Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 2013; 1: 51–60.; Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1: 199–209.; Zhong N., Wang C., Zhou X. et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Intern. J. COPD. 2015: 10: 1015–1026.; Geitona M., Kousoulakou H., Kalogeropoulou M. et al. Cost-effectiveness analysis of the fixed combination indacaterol/glycopyrronium vs. tiotropium and salmeterol/fluticasone in the management of COPD in Greece. Value Health. 2015; 18 (7): A500.; Rutten-van Mölken M.P., Goossens L.M. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012; 30 (4): 271–302.; Price D., Keininger D., Costa-Scharplatz M. et al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir. Med. 2014; 108 (12): 1786–1793.; Asukai Y., Baldwin M., Fonseca T. et al. Improving clinical reality in chronic obstructive pulmonary disease economic modelling: development and validation of a micro-simulation approach. Pharmacoeconomics. 2013; 31: 151–161.; https://journal.pulmonology.ru/pulm/article/view/675

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/675
https://doi.org/10.18093/0869-0189-2016-26-1-73-78

المؤلفون: E. Ermakova I., V. Balan E., Е. Ермакова И., В. Балан А.

المصدر: Obstetrics, Gynecology and Reproduction; Vol 5, No 3 (2011); 16-21 ; Акушерство, Гинекология и Репродукция; Vol 5, No 3 (2011); 16-21 ; 2500-3194 ; 2313-7347

مصطلحات موضوعية: m-cholinergic antagonist, m-cholinoblokers, m-anticholinergics, OAB, estriol, антагонисты м-холинорецеп- торов, м-холиноблокаторы, м-холинолитики, ГАМП, эстриол

وصف الملف: application/pdf

Relation: https://www.gynecology.su/jour/article/view/275/378; Балан В.Е Урогенитальные расстройства в климактерии (клиника, диагностика, заместительная гормонотерапия): Дис. … докт. Мед. Наук. -М. -1988.; Балан В.Е., Гаджиева З.К. Нарушения мочеиспускания в климактерии и принципы их лечения//Русский медицинский журнал. -2000. -Т. 8. -№ 7. -С.; Великая С.В. Совершенствование диагностики и терапии императивных нарушений мочеиспускания у женщин с урогенитальными расстройствами в климактерии: Дисс. … канд. Мед. Наук. -М.-2003.; Вишневский Е.Л., Пушкарь Д.Ю., Лоран О.Б., Данилов В.В., Вишневский А.Е.//Урофлоуметрия. -М.: 2004. -С. 263; С. 176-183; 183-208.; Кулаков В.И., Аполихина И.А. Недержание мочи у женщин: новые возможности в диагностике и лечении//Гинекология. -2004. -Т. 4. -№ 3. -С. 103 -105.; Петрова В.Д. Недержание мочи у женщин (этиопатогенез, клиника, диагностика, лечение)//Дис. … докт. мед. наук. -М. -2005.; Пушкарь Д.Ю. Диагностика и лечение сложных и комбинированных форм недержания мочи у женщин: Автореф. дис. … д-ра мед. наук. -М., 1996. -34 с.; Сивков А.В., Ромих В.В. Фармакотерапия гиперактивного мочевого пузыря//Consilium medicum. -2002. -№ 7. -С. 348 -354.; Aggazzotti G., Pesce F., Grassi D., Fantuzzi G., Righi E., De Vita D., Santacroce S., Artibani W. Prevalence of urinary incontinence among institutionalized patients: a cross-sectional epidemiologic study in a midsized city in northern Italy//Urology. -2000. -V. 156. -№ 2. -P. 245 -249.; Cruz F. Vanilloid receptor and detrusor instability//Neurology and Urodynamics.-2009.-P. 29 -34.; Сardozo L., Lose., Vc Clish D., Versi E., de Koning Gans H. A systematic review of estrogens for recurrent urinary tract infections: third report of the hormones and urogenital therapy (HUT) committee//Int. Urogynecol J. Pelvic Floor Dysfunct. -2001. -12.-P. -P. 15 -20.; Сardozo L, Staskin D. Textbook of female urology and urogynaecology -2005. -P.183 -227.; Fitzgerald M.P., Brubaker L. Urinary incontinence symptom scores and urodynamic diagnoses.//Neurourol. Urodin. -2002. -21. -P. 30 -35.; Hann-Chorng Kuo,Hsin-Tzu Liu, Michael B. Chancellor Urinary Nerve Growth Factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence//Neurology and Urodynamics.-2009.-P. 24 -28.; Jackson S., James M., Abrams P/The effect of oestradiol jn vaginal collagen metabolism in postmenopausal women with genuine stress incontinence//BJOG. -2002. -Vol. 109. -P.339 -344.; Lingman K. Genuine stress incontinence//Current Obstet Gynecol. -2001. -Vol. 2. -P. 353-358.; Liu HT, Kuo HC. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention//Neurourol Urodyn. -2009.-28(1): Р.78-81.; Маdersbacher S., Haidinger G., Waldmuller J. Urinary incontinence in both sexes-prevalence rates, impact on quality of life and sexual life.//Eur. Urol. -2000. -V. 37. -P. 2.; Moller L.A., Lose G., Jorgensen T. Risk factors lower urinary tract symptoms in women 40 to 60 years of age//Obstet. Gynecol. -2000. -Vol. 96. -P. 446 -451.; Monz D., Pons M., Hampel C., Hunskaer S., Quail D., Samsioe G., Sykes D., Wagg A., Papanicolaou S. Patien -repoted impact of urinary incontinence. -Results from treatment seeking women in 14 European countries//Maturitas. -2005. -V. 52. -№ 2. -Р. 25 -28.; Moore K.H. Conservative management for urinary incontinence//Baillieres Best. Pract. Res. Clin. Obstet. Gynecol. -2000. -Vol. 14. -№ 2. -Р. 251 -289.; Stenberg F., Heimer G., Ulmsten U. The prevalence of urogenital symptoms in postmenopausal women//Maturitas. -1995. -№ 22. -Suppl. -P. 17-20.; Van de Vaart C.H. et al. The contribution of hysterectomy to the occurrence of urge and stress urinary incontinence symptoms//Br. J. Obstet Gynecol. -2002. -Vol. 109. -P. 149-151.; Yokoyama T., Kumon H., Nagai A. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder/Neurourol. Urodin.-2008.-V.27, P.417 -420; https://www.gynecology.su/jour/article/view/275

الاتاحة: https://www.gynecology.su/jour/article/view/275

المؤلفون: Yu. G. Alyaev, Z. K. Gadzhieva, L. M. Rapoport, Yu. B. Kazilov, Ю. Г. Аляев, Заида Камалудиновна Гаджиева, Л. М. Рапопорт, Ю. Б. Казилов

المصدر: Andrology and Genital Surgery; Том 15, № 1 (2014); 6-14 ; Андрология и генитальная хирургия; Том 15, № 1 (2014); 6-14 ; 2412-8902 ; 2070-9781 ; 10.17650/2070-9781-2014-1

مصطلحات موضوعية: солифенацин, α-adrenoblockers, M-cholinoblockers, selectivity, tamsulosin, silodosin, solifenacin, α-адреноблокаторы, М-холиноблокаторы, селективность, тамсулозин, силодозин

وصف الملف: application/pdf

Relation: https://agx.abvpress.ru/jour/article/view/78/72; Chapple C. R., Roehrborn C. G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651.; Oelke M., Bachmann A., Descazeaud A. et al. Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO), 2013.; Ahlquist R. P. A study of the adrenotropic receptors. Am J Physiol 1948;153(3): 586–600.; Roehrborn C. G., Mc Connel J., Barry M. J. et al. Guideline on the Management of Benign Prostatic Hypertrophy, AUA. http://www.auanet.org / content /guidelines-and-quality-care / clinical-guidelines / main-reports / bph-management /preface_toc. pdf.; Milani S., Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on α1-adrenoceptor antagonists. BJU Int 2005;95(Suppl 4):29–36.; Van Dijk M. M., de la Rosette J. J., Michel M. C. Tamsulosin – modified-release and oral controlled absorption system formulation in the treatment of benign prostatic hyperplasia. Therapy 2006;3:237–46.; Nickel J. C., Sander S., Moon T. D. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547–59.; Michel M. C., Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147(Suppl 2):S88–119.; Guimaraes S., Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001;53:319–56.; Rudner X. L., Berkowitz B. A., Booth J. V. et al. Subtype specific regulation of human vascular α1-adrenergic receptors by vessel bed and age. Circulation 1999;100:2336–43.; Michel M. C., Kenny B. A., Schwinn D. A. Classification of α1-adrenoceptor subtypes. Naunyn Schmiedeberg’s Arch Pharmacol 1995;352:1–10.; Zhu J., Taniguchi T., Takauji R. et al. Inverse agonism and neutral antagonism at a constitutively active alpha1a-adrenoceptor. Br J Pharmacol 2000;131:546–52.; Hein P., Goepel M., Cotecchia S., Michel M. C. A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster α1B-adreno ceptors. Naunyn Schmiedeberg’s Arch Pharmacol 2001;363:34–9.; Zhang L., Taniguchi T., Tanaka T. et al. Alpha-1 adrenoceptor up-regulation induced by prazosin but not KMD-3213 or reserpine in rats. Br J Pharmacol 2002;135:1757–64.; Nagai A., Hara R., Yokoyama T. et al. Ejaculatory dysfunction caused by the new α1-blocker silodosin: a preliminary study to analyze human ejaculation using color Doppler ultrasonography. Int J Urol 2008;15:915–8.; Marks L. S., Gittelman M. C., Hill L. A. Rapid efficacy of the highly selective A1-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634–40.; Kawabe K., Yoshida M., Homma Y. Silodosin, a new a1A-adrenoceptorselective antagonist for treating benign prostatic hyperplasia: a results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019–24.; Speakman M. J., Snijder R. J., Anthonijs G., Doyle C. A. Patients on tamsulosin experiencing abnormal ejaculation choose to remain longer in clinical trials and have slightly better improvement in symptom score than other patients abstract. J Urol 2003;169(Suppl 4):334.; Roehrborn C. G., Lepor H., Kaplan S. A. et al. Retrograde ejaculation induced by silodosin is associated with greater urodynamic and symptomatic improvement in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Podium presentation at the 85th annual meeting of the Western Section of the American Urological Association, October 25–29, 2009.; Лепор Г. Альфа-блокаторы: отбор на селективность. Истинно селективный альфа-блокатор. Урол сегодня 2013;3(25):3.; Говоров А. В. Альфа-блокаторы: отбор на селективность. Альфа-блокаторы: уроселективность по максимуму. Урол сегодня 2013;3(25):1–2.; Монторси Ф. Альфа-блокаторы: отбор на селективность. Альфа-блокаторы: наука в фокусе. Урол сегодня 2013;3(25):4.; Мельников А. В. Послеоперационная острая задержка мочеиспускания: Дис. … канд. мед. наук. М., 2002. 136 c.; Tatemichi S., Kobayashi K., Maezawa A. et al. α1-Adrenoceptor subtype selectivity and organ specifi city of silodosin (KMD-3213). Yakugaku Zasshi 2006;126:209–16.; Watanabe T., Ozono S., Kageyama S. A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. J Int Med Res 2011; 39(1):129–42.; Marks L. S., Gittelman M. C., Hill L. A. et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181(6):2634–40.; Chapple C., Montorsi F., Tammela T. et al.; European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011;3(59):342–52.; Montorsi F. Profile of silodosin. Eur Urol 2010;4(Suppl 9):491–5.; Яровой С. К. Силодозин – новый препарат группы селективных α1-адреноблокаторов. Экспер и клин урол 2012;3:57–62.; ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy. Final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 2003;42:239–46.; ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288(23):2981–97.; Blaivas J., Marks B., Weiss J. et al. Differential diagnosis of overactive bladder in men. J Urol 2009;182(6):2814–7.; Abrams P. H., Farrar D. J., Turner-Warwick R. T. et al. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979;121:640–2.; Гаджиева З. К. Уродинамические исследования в диагностике и лечении нарушений мочеиспускания: Дис. … д-ра мед. наук. М., 2009.; Тангриберганов М. Р. Особенности лечения доброкачественной гиперплазии предстательной железы в сочетании с клиническими симптомами гиперактивного мочевого пузыря: Дис. … канд. мед. наук. М., 2011.; Ohtake A., Ukai M., Hatanaka T. et al. In vitro and in vivo tissue selectivity profile of Solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004;492:243–50.; Chapple C., Herschornb S., Abrams P. et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009;56(3):534–41.; Abdel-Khalek M., Nabieh A., Ibrahiem E. Do muscarinic receptors of the prostate have a significant role in the pathophysiology of bladder outlet obstruction? phase 1 (in vitro) study. Eur Urol Suppl 2006;5(2):120.; Козырев С. В. Диагностика и лечение гиперактивного мочевого пузыря у больных доброкачественной гиперплазией предстательной железы: Дис. … канд. мед. наук. М., 2008.; Saito H., Yamada T., Oshima H. et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and / or urinary incontinence. Jpn J Urol Surg 1999;12:525–36.; Athanasopoulos A., Gyftopoulos K., Giannitsas K. et al. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169:2253–6.; Lee K. S., Kim D. Y., Kim J. C. et al. Combination treatment with propiverine hydrochloride plus doxazosin gits in men with overactive bladder coexisting benign prostatic obstruction: a prospective, randomized, controlled, multicenter study. ICS annual meeting, 2004 (abstr. 207).; Lee K. S., Choo M. S., Kim D. Y. et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and; coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005;174:1334–8.; Kaplan S. A., Roehrborn C. G., Rovner E. S. et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296 (19):2319–28.; MacDiarmid S.A., Peters K. M., Chen A. et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008;83(9): 1002–10.; Drake M., Chapple C., van Kerrebroeck P. et al. Efficacy of combination therapy with tamsulosin OCAS and solifenacin in NEPTUNE: Results from a randomised, phase 3 trial in men with LUTS. Eur Urol 2012; EAU abstracts #746H.; https://agx.abvpress.ru/jour/article/view/78

الاتاحة: https://agx.abvpress.ru/jour/article/view/78
https://doi.org/10.17650/2070-9781-2014-1-6-14

المؤلفون: Ермакова, Е., Балан, В.

مصطلحات موضوعية: АНТАГОНИСТЫ М-ХОЛИНОРЕЦЕПТОРОВ, М-ХОЛИНОБЛОКАТОРЫ, М-ХОЛИНОЛИТИКИ, ГАМП, ЭСТРИОЛ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/optimizatsiya-metodov-lecheniya-urogenitalnyh-narusheniy-u-zhenschin-v-klimakterii
http://cyberleninka.ru/article_covers/14498789.png

المؤلفون: Гиляров, А.

مصطلحات موضوعية: НЕЙРОЛЕПТИКИ,СИНДРОМ ПАРКИНСОНА,М-ХОЛИНОБЛОКАТОРЫ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/primenenie-m-holinolitikov-tsentralnogo-deystviya-dlya-korrektsii-ekstrapiramidnyh-rasstroystv-vyzvannyh-neyroleptikami-1
http://cyberleninka.ru/article_covers/15021664.png

المصدر: Health of Man; № 3 (2019); 27-32
Здоровье мужчины; № 3 (2019); 27-32
Здоров'я чоловіка; № 3 (2019); 27-32

مصطلحات موضوعية: нейрогенный гиперрефлекторный мочевой пузырь, солифенацин, селективные м-холиноблокаторы, 616.62-008.222-02:616.8-08, нейрогенний гіперрефлекторний сечовий міхур, соліфенацин, селективні м-холіноблокатори, neurogenic hyperreflex bladder, solifenacin, selective m-anticholinergics

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=scientific_p::ffa69c97ea787f03ce050bb2b7f934b8
http://health-man.com.ua/article/view/185347

المصدر: Акушерство, гинекология и репродукция.

مصطلحات موضوعية: АНТАГОНИСТЫ М-ХОЛИНОРЕЦЕПТОРОВ, М-ХОЛИНОБЛОКАТОРЫ, М-ХОЛИНОЛИТИКИ, ГАМП, ЭСТРИОЛ

وصف الملف: text/html

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______2806::c75f501b64b1b11fe73e0bfebea0d3f5
http://cyberleninka.ru/article/n/optimizatsiya-metodov-lecheniya-urogenitalnyh-narusheniy-u-zhenschin-v-klimakterii

المصدر: Вестник Санкт-Петербургского университета. Серия 11. Медицина.

مصطلحات موضوعية: НЕЙРОЛЕПТИКИ,СИНДРОМ ПАРКИНСОНА,М-ХОЛИНОБЛОКАТОРЫ

وصف الملف: text/html

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______2806::90fb2e189f59e0649352f2ffc8496c01
http://cyberleninka.ru/article/n/primenenie-m-holinolitikov-tsentralnogo-deystviya-dlya-korrektsii-ekstrapiramidnyh-rasstroystv-vyzvannyh-neyroleptikami-1